
Please try another search
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines. Its lead clinical-stage program includes ORX750, an orally administered OX2R agonist in a Phase 2a study for the treatment of idiopathic hypersomnia and narcolepsy type 1 and 2. The company also develops ORX142 for the treatment of neurological and neurodegenerative disorders, as well as other potential symptoms, including excessive daytime sleepiness, impaired attention, cognitive deficits, and fatigue; and ORX489 for the treatment of neuropsychiatric disorders. In addition, it offers LockBody, which is designed to selectively drive potent effector function activity, such as CD3, into the tumor microenvironment. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.
Name | Age | Since | Title |
---|---|---|---|
Carol Stuckley | 70 | 2021 | Independent Non-Executive Director |
Brett I. W. Zbar | 53 | 2021 | Independent Non-Executive Director |
Arjun Goyal | 43 | 2021 | Independent Non-Executive Director |
Mathias Hukkelhoven | 72 | 2022 | Independent Non-Executive Director |
Mary Lynne Hedley | 63 | 2021 | Independent Non-Executive Director |
Francesco de Rubertis | 55 | 2020 | Independent Non-Executive Chairman of the Board |
Samarth Kulkarni | 47 | 2021 | Independent Non-Executive Director |
Saurabh Saha | 49 | 2021 | CEO & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review